AGM Chairman’s address and CEO’s presentation
Melbourne, Australia: Attached is the Chairman’s address together with the CEO’s presentation to the Annual General Meeting of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), to be held at 4.00pm today.
VivaGel® condom receives regulatory approval in Europe
Starpharma today announced that it has been granted marketing approval for the VivaGel® condom in Europe.
2019 AGM details
Starpharma today notifies that its 2019 AGM will be held at 4pm on 21 November 2019 at RACV City Club, Level 2, 501 Bourke Street, Melbourne, Victoria.
The AGM will be recorded and available via webcast later that day. To access the webcast, participants can register via the following link:
https://webcasting.boardroom.media/broadcast/5dccc1f06242591605116cb6
UK launch of VivaGel® BV
Starpharma today announced that VivaGel® BV has been launched in the UK under the brand Betafem® BV Gel. This launch follows the first European launches in June 2019, including in Germany and other countries.
Starpharma tech ready to deliver
The Austraian published an interview with Starpharma CEO Dr Jackie Fairley where she discussed the potential of the dendrimer technology, how it is applied to cancer drugs and the potential benefits it provides to patients.
To read the full article, click here. (paywall)
Dendrimer drug delivery enhances chemotherapy gemcitabine in human pancreatic mode
Online pharmaceutical publication Pharma in Focus noted Starpharma’s positive DEP® gemcitabine results in a human pancreatic model, noting it was one of multiple DEP® drugs from the company.
To read the full article, click here.